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Introduction: Coronary allograft vasculopathy (CAV) is one of the main factors limiting long-
term survival following orthotopic heart transplantation (HTx). Whether or not and, if so,
how donor-transmitted atherosclerosis (DCA) affects the post-transplant course of the
allograft recipient is still unclear. Conventional coronary angiography is a moderately
accurate technique for DCA detection as it will reveal only the more gross morphological
lesions. By contrast, intravascular ultrasound (IVUS) has been shown to be a much more
sensitive technique for CAV and DCA detection. In our study we sought to determine the
prevalence of DCA in our HTx patient population and identify main risk factors of DCA
based on donor characteristics.
Patients and methods: We performed a retrospective analysis of data of 119 patients (92
men, 27 women) undergoing transplantation in our center from August 2006 through
September 2012, who had survived their ﬁrst post-transplant month and had coronary
angiography and IVUS.
Results: DCA was present in 39 patients, and not documented in 80 patients. The main risk
factors for DCA included donor age, cigarette smoking, and hypertension; the other
parameters were not shown to be statistically signiﬁcant. In-hospital mortality was low
in both groups (DCA positive and DCA negative), with one patient dying in either group.
One-year mortality rates post-HTx were likewise almost identical in both groups (15.4%
and 15% in DCA positive and negative, respectively).ch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
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.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 0 9 – e 3 1 4e310Conclusion: The prevalence of DCA in our patients was 32.8%, with major risk factors for
DCA including donor age, cigarette smoking, and hypertension. As age seems to be the
strongest predictor, coronary angiography should be a routine examination in individuals
aged over 40 years; the examination should be considered in younger individuals with a
cluster of several of risk factors. The 1-year survival in this selected patient population was
identical in both groups, the implication being that the diagnosis of DCA had no effect on
1-year survival post-HTx.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Heart transplantation still remains to be the method of choice in
selected patients with end-stage heart failure. At present, survi-
val half-life of patients post-HTx is longer than 11 years, with the
main factor precluding longer survival being coronary allograft
vasculopathy. The paucity of suitable younger donors makes us
accept increasingly older donors more likely to have coronary
atherosclerosis. According to the International Society of Heart
and Lung Transplantation (ISHLT) registry, the mean age of
donors is 40.2 years in Europe, and 31.6 years in North America.
While, 5 years ago, individuals aged 50 made up only 20% of all
donors, the ﬁgure was as high as 30% last year [1]. The mean age
of donors in our center was 33 years 10 years ago, 38 years 5
years ago, 40 years last year, and as high as 45 years this year.
These data clearly indicate that the prevalence of donor-
transmitted atherosclerosis is going to increase. In his study,
Tuzcu reported that atherosclerotic lesions in the coronary
arteries are present in one in six teenagers. Judging by the above
study, the prevalence of atherosclerosis could potentially vary
between 17% in donors below 20 years of age and 85% in those
aged over 50. Given the sedentary way of life, low physical
activity, and obesity in children and young individuals, this trend
is most unlikely to reverse [2]. Both the increasing donor mean
age and the development of coronary atherosclerosis at an
increasingly younger age as well as the fact that CAV continues
to be the Achilles' heel in the ﬁeld of heart transplantation led to
the need for a proper deﬁnition of CAV and standardization of
terms within this specialty. In addition to the established terms
of IVUS-based classiﬁcation of atherosclerosis (atheromas, calci-
ﬁcations, plaque and thrombi), several studies have shown
association betweenmaximal intimal thickness (MIT) of coronary
arteries and adverse cardiovascular outcomes following HTx [3,4].
The cutoff value widely used is MIT ≥0.5mm. In the ISHLT
Consensus Statement on standardized nomenclature for cardiac
allograft vasculopathy, the panel of experts admits that “IVUS-
detected maximal intimal thickening may be most useful for its
negative predictive value at any time after transplant; however,
we do not see a role for routine IVUS surveillance. IVUS-deﬁned
intimal thickening is predictive of developing angiographic CAV
and may guide treatment, but this remains speculative”.
Therefore we decided to conduct an observational study aimed
at determining the relationship between angiographic and IVUS
ﬁnding on coronary arteries early after HTx and long-term
outcomes (angiographic and/or IVUS CAV, myocardial infarction
and mortality). In this manuscript we present data on the
prevalence of CAV related ﬁndings found shortly after HTx and
compare the results with other studies.2. Patient group and methods
A total of 150 heart transplantations in 118 men and
32 women were performed in our center between August
2006 and September 2012. We made a retrospective analysis
of database data from 119 of our patients surviving the ﬁrst
post-transplant month and had coronary angiography and
IVUS. Table 1 shows the basic characteristics of the patient
population and Table 2 presents the basic characteristics of
the respective graft donors.3. Immunosuppression and endomyocardial
biopsy
All patients were treated using an immunosuppressive pro-
tocol with a conventional triple combination of cyclosporine
A (Sandimmunn Neoral, Novartis) or tacrolimus (Prograf,
Advagraf, Astellas Pharma), mycophenolate mofetil (Cellcept,
Roche), and corticosteroids. All patients received induction
therapy with monoclonal antibodies, initially daclizumab
(Zenapax, Roche) or basiliximab in the last 2 years (Simulect,
Novartis). Endomyocardial biopsy was performed as per
protocol once a week in the ﬁrst month post-HTx and,
subsequently, once a month until a total of 10 biopsies over
the ﬁrst post-transplant year. Histological ﬁndings were
evaluated using the Banff classiﬁcation.4. Technique for intravascular ultrasound and
measurement
Intravascular ultrasound (IVUS) was performed 3–4 weeks
post-HTx. Following heparin administration, a 6F catheter
was advanced into the left coronary artery using a guidewire.
In patients 0.4 mg sublingual nitroglycerin was administered
before advancing the IVUS catheter. Next, IVUS catheter
(Volcano Eagle Eye Platinum) was inserted distally to the left
anterior descending artery (LAD) over an ultrathin guidewire
and pulled manually proximally from the distal segment of
the artery. Patients with documented calciﬁcations and/or
atheromas within the visualized course of the artery were
deﬁned as a group with donor-transmitted atherosclerosis
(DCA). Coronary atheromas and calciﬁcations have been
validated according to the ACC Clinical Expert Consensus
published previously [5–7]. In patients without DCA, max-
imum intima–media thickness (MIT) was measured at two
pre-deﬁned sites, bifurcations of LAD and r. circumﬂex (RC),
Table 1 – Basic characteristics of recipients examined by ICUS.
Variable Statistics DCA positive N¼39 DCA negative N¼80 pn
Sex
Male
Female
N (%) 32 (82.1%) 60 (75.0%) 0.389
N (%) 7 (17.9%) 20 (25.0%)
Age (yrs) Mean (SD) 50.7 (11.86) 50.6 (11.19) 0.823
Median (Q1-Q3) 53.0 (43.0–61.0) 54.0 (43.0–59.5)
Min–Max 21–66 21–66
Number of rejection episodes
1
2
3
4
N (%) 27 (69.2%) 50 (62.5%) 0.239
N (%) 8 (20.5%) 15 (18.8%)
N (%) 2 (5.1%) 8 (10.0%)
N (%) – 5 (6.3%)
N (%) 2 (5.1%) 2 (2.5%)
SD¼standard deviation, Q1¼ lower quartile, Q3¼upper quartile.
n p value in the Mann–Whitney test for comparison of continuous variables between groups, or the chi-square test for comparison of
categorical variables.
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measurement is important for the follow-up analysis, which
will be the subject of further investigation.5. Statistical analysis
Basic characteristics of recipients and donors were presented
using the methods of descriptive analysis. Results are given
as mean with standard deviation (SD), median, lower quartile
(Q1), upper quartile (Q3), minimum and maximum with
continuous variables, and using absolute and relative num-
bers with categorical variables.
The endpoints were compared between patients divided
by DCA positivity or negativity. Categorical variables were
compared using the chi-square test or, possibly, Fisher's test.
As continuous variables do not show a normal distribution
pattern, the non-parametric Mann–Whitney test was
employed to compare inter-group parameters.
Any association between coronary heart disease and DCA
incidence was determined using univariate and multivariate
logistic regression models. Results are given as the odds ratio
(OR) and its 95% conﬁdence interval.
All analyses were conducted at a level of 5% signiﬁcance
(i.e., p values o0.05 are considered statistically signiﬁcant).6. Results
We reviewed data from 119 HTx patients from our database.
Baseline demographic data of the recipients are shown in
Table 1. There was no statistically signiﬁcant difference in
age, gender and rejections between subjects with and without
documented DCA.
Based on IVUS ﬁndings acquired 3.471.1 weeks after
transplantation, we documented DCA in 39 (32.8%) patients
with donor hearts. Out of 80 patients without documented
IVUS signs of DCA, mean MIT was 0.4470.28 mm. When
using the cutoff of 0.5 mm, 59 (74%) patients had MIT less
than 0.5 mm.Table 2 shows the association between the risk factors for
coronary heart disease in donors and DCA. Using univariate
logistic regression models, donor age, cigarette smoking and
hypertension were identiﬁed as predictors of DCA incidence
in our group of patients.
Multivariate logistic regression analysis identiﬁed donor
age and the presence of at least another two risk factors for
coronary heart disease (hypertension, smoking, diabetes
mellitus, hyperlipoproteinemia, male sex, or obesity) as
independent predictors of the DCA (Table 3). Based on the
results of our study, donor age seems to be the most
signiﬁcant independent predictor of DCA. Age over 45 in
men and 55 in women raises the odds ratio for having DCA
by a factor of 6.5 when compared with younger donors
(OR¼6.48; 95% CI¼2.638; 15.937). Presence of at least one of
the above risk factors for coronary heart disease increases the
odds for having DCA by a factor of 3.5 (OR¼3.48; 95%
CI¼1.431; 8.504).7. Discussion
Based on the analysis of single-center retrospectively col-
lected data from 119 heart recipients, we found signs of DCA
in one third of our HTx patient population. We have also
identiﬁed a subgroup of patients with increased MIT as a
surrogate of impaired outcome. When reviewing a rather
limited body of evidence in the literature, we found very good
agreement with data from other groups. Li et al. reported
prevalence of donor lesions in 30% of HTx population [8]. In
case we applied their deﬁnition of pre-existing donor lesions
including MIT ≥0.5 mm, the prevalence of DCA would have
been higher in our patient population. This ﬁnding can be
explained by signiﬁcant difference in donor population age in
both studies (29.6712.7 vs. 42.1710.9 years). Furthermore,
Konig et al. studied a total of 18 patients using IVUS including
Virtual Histology and demonstrated donor transmitted cor-
onary atherosclerosis in 33% [9].
Based on the results, we have clearly identiﬁed age, tobbaco
abuse and hypertension as risk factors of DCA. Other conven-
tional risk factors of CAD (diabetes, hyperlipoproteinemia, male
Table 2 – Basic characteristics of donors.
Variable Statistics DCA positive N¼39 DCA negative N¼80 pn
Sex
Male
Female
N (%) 32 (82.1%) 59 (73.8%) 0.316
N (%) 7 (17.9%) 21 (26.2%)
Age (yrs) Mean (SD) 49.5 (6.72) 34.6 (12.39) o0.001
Median (Q1-Q3) 51.0 (45.0–54.0) 33.0 (23.0–45.5)
Min–Max 21–66 21–66
Diabetes mellitus
Yes
No
Unknown
N (%) 2 (5.1%) 1 (1.3%) 0.207
N (%) 26 (66.7%) 66 (82.5%)
N (%) 11 (28.2%) 13 (16.2%)
Hypertension
Yes
No
Unknown
N (%) 14 (35.9%) 11 (13.8%) 0.005
N (%) 21 (53.8%) 60 (75.0%)
N (%) 4 (10.3%) 9 (11.2%)
Smoking
Yes
No
Unknown
N (%) 13 (33.3%) 11 (13.8%) 0.017
N (%) 16 (41.0%) 44 (55.0%)
N (%) 10 (25.6%) 25 (31.3%)
Hyperlipoproteinemia
Yes
No
Unknown
N (%) 3 (7.7%) 4 (5.0%) 0.368
N (%) 18 (46.2%) 56 (70.0%)
N (%) 18 (46.2%) 20 (25.0%)
Obesitya
Yes
No
Unknown
N (%) 4 (10.3%) 6 (7.5%) 0.727
N (%) 35 (89.7%) 74 (92.5%)
N (%) – –
Total number of risk factors
0
1
2
3
4
N (%) 2 (5.1%) 15 (18.8%) o0.001
N (%) 7 (17.9%) 36 (45.0%)
N (%) 13 (33.3%) 19 (23.8%)
N (%) 9 (23.1%) 8 (10.0%)
N (%) 8 (20.5%) 2 (2.5%)
SD¼standard deviation, Q1¼ lower quartile, Q3¼upper quartile.
n p value in the Mann–Whitney test for comparison of continuous variables between groups, or the chi-square test for comparison of
categorical variables.
a BMI430 kg/m2.
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partly due to selection bias with lack of detailed data on
personal history of donors. When adding a multivariate analy-
sis, a cumulative effect of risk factors was found.
Donor hearts with DCA are more prone to acute graft failure
immediately post-transplant, and may later progress more
rapidly to CAV; both these conditions are the two most common
causes of morbidity and mortality post-HTx [10–12]. To be able to
determine whether the problem is not DCA but true CAV, it is
critical to have adequate information about the actual status of
donor coronary arteries. While a number of centers require
coronary angiography prior to HTx in patients aged over 40,
the examination is unavailable in some, and others do not insist
on performing the examination. Moreover, coronary angiography
provides just a quick look at coronary arteries and is deﬁnitely
less accurate than IVUS. As reported by Tuzcu et al. [2], none of
their donors below 30 years of age showed abnormal coronary
angiograms, yet IVUS demonstrated atherosclerosis in 28% of
them. Besides, given the scarcity of donors, insigniﬁcant lesionsshown in donor coronary angiograms (stenoses o30%) do not
pose a reason for disqualifying the graft. It is just the presence of
these “insigniﬁcant narrowings” that may result in faster devel-
opment of CAV. Whatever the case, knowledge of the patient's
initial status in the early post-transplant period is the most
important factor playing a pivotal role in their fate.
One of the ﬁrst studies reporting on the association
between the outcome of IVUS-based examination and post-
HTx outcome was conducted by Mehra et al. [13] showing that
patients with intimal thickening 40.5 mm experienced more
myocardial infarctions, there were more deaths in their sub-
group, and patients required more re-transplant procedures
during a 4-year follow-up. Perhaps even more importantly,
Rickenbacher reported an adverse effect of intimal thickening
40.3 mm [14]. Patients with these values were shown to have
signiﬁcantly worse 4-year survival rates (73% vs 96%). It was
just the absence of IVUS assessment immediately post-
transplant and, consequently, the inability to distinguish
DCA from CAV that were the main limitations of Mehra et al.'s
Table 3 – Association between donor risk factors for coronary heart disease and incidence of DCA.
OR (95% CI)
Agea 7.54 (3.175; 17.920)
Hypertension 3.64 (1.430; 9.244)
Smoking 3.25 (1.212; 8.708)
Diabetes mellitus 5.08 (0.441; 58.420)
Hyperlipoproteinemia 2.33 (0.477; 11.423)
Male sex 1.63 (0.624; 4.238)
Obesityb 1.41 (0.374; 5.316)
OR¼Odds ratio, CI¼conﬁdence interval.
a Age over 45 in males and 55 in females.
b BMI430 kg/m2.
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the same intima–media thickness at 3 years post-HTx may,
but need not, result in cardiac events occurring in these
patients [15]. When evaluating the effect of the rate of intimal
thickening progression on a patient's fate post-HTx, Kapadia
noted that rapid intimal thickening progression (40.5 mm)
over the ﬁrst post-transplant year increases the risk for serious
cardiac events in that patient subgroup (myocardial infarction,
death, heart failure) [16]. The authors of studies examining the
effect of DCA on long-term survival post-transplant have
reported inconsistent data. In their series of 301 patients, Li
et al. documented a frequent incidence of DCA (in up to 30% of
patients) yet found no effect of DCA on the rate of intimal
thickening progression and survival of patients having HTx [8].
By contrast, Yamasaki, Gao, and Wong showed that the
presence of donor-transmitted atherosclerotic plaques is
associated with their more rapid progression and accelerates
the rate of allograft vasculopathy post-HTx [10,11,17].
Coronary artery atherosclerosis in non-transplant patients
is mostly due to dyslipidemia whose treatment, particularly
with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins), clearly improves the prognosis
of these patients, prevents progression of atherosclerotic
plaques while stabilizing them [18–20]. Statins have also been
found beneﬁcial in transplant recipients who often develop
dyslipidemia. Hence, statins have become an integral part of
therapeutic protocols perhaps in all centers performing heart
transplantation. In these patients, statins reduce the risk for
sudden death and incidence of severe acute cellular rejection
episodes, and arrest or at least slow the development of CAV
[21–24].
In their IVUS study, Wenke et al. even documented a
reduction in MIT over the ﬁrst post-transplant year in an
average 50% of statin-treated recipients compared with those
not receiving statins [25].
Potential pharmacological options in modulating and slow-
ing the rate of DCA progression may include angiotensin-
converting enzyme (ACE) inhibitors, calcium-channel blockers
and, in particular, TOR inhibitors (sirolimus, everolimus). An
IVUS study by Mehra exploring the effect of ACE inhibitors and
calcium-channel blockers reported that patients treated with
some of these drug classes showed smaller intimal thickening
compared with a control group [26].
Another possible approach is to modify the immunosup-
pressive protocol by instituting TOR inhibitors as soon aspossible after transplantation. A number of studies demon-
strated a signiﬁcant antiproliferative potential of these agents
in terms of reducing and slowing that rate of CAV progression
and, consequently, improved long-term survival after heart
transplantation [27–30].
Our study has several limitations. First is the retrospective
design of the study. Second is the relatively small number of
study subjects, but this is the major problem of most of the
single center studies performed in HTx patients. It was also
the main reason for a relatively long period of enrollment of
the patients. Finally, Virtual Histology was not a part of IVUS
examination, since this application has not been available for
all exams.8. Conclusion
The prevalence of DCA in our patients was almost 33%. The
major risk factors implicated in donor DCA have been
identiﬁed to be donor age, cigarette smoking, and hyperten-
sion. As age seems to be the strongest predictor, coronary
angiography should be a routine examination in individuals
aged over 40 years; the examination should be considered in
younger individuals with a cluster of several risk factors.Acknowledgment
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